Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint
Links shared publicly online about this topic.
- 201total visits
Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint
Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.
View full resource at news-medical.net
Tags: Seizure, Seizure Medication, Epilepsy, Fibromyalgia Medication, Neuropathic Pain Medication, Lyrica, Pfizer, News
Most Recently Shared on June 22, 2011 at 8:34 am By:
Epilepsy News: Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint: Pfizer Inc. annou... http://bit.ly/irWH6C
Also Shared By:
Advertisement
News-Medical.Net
@NewsMedical
Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint: Pfizer Inc. announced today that... http://bit.ly/irWH6C
1 year ago...